Stryker Corp ( (SYK) ) has released its Q4 earnings. Here is a breakdown of the information Stryker Corp presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Stryker Corp is a global leader in medical technology, specializing in MedSurg, Neurotechnology, and Orthopaedics, committed to enhancing healthcare outcomes. In its latest earnings report, Stryker Corp announced a 10.7% increase in net sales for the fourth quarter of 2024, amounting to $6.4 billion, and a 10.2% growth for the full year totaling $22.6 billion. While the reported EPS dropped by 52.7% in the fourth quarter, the adjusted EPS rose by 15.9% to $4.01, highlighting the company’s financial resilience. Key financial metrics revealed a strong performance with an adjusted operating income margin increase of 200 basis points to 29.2% for the fourth quarter. Additionally, the company reported a significant growth in its MedSurg and Neurotechnology, and Orthopaedics segments, with organic sales consistently increasing by over 10% both in the quarter and year. Looking ahead to 2025, Stryker anticipates organic net sales growth between 8% and 9% and projects adjusted net earnings per diluted share to range from $13.45 to $13.70, indicating continued positive momentum supported by procedural volumes and capital product demand.
